近年来随着中国加快卫生信息化建设工作，医疗信息化市场规模持续平稳增长，根据统计，近三年中国医疗行业IT应用总体投资平均增长率达到27.6%。2012年总体投资规模达到268.1亿元。

新型农村合作医疗试点工作开展以来，各地认识明确，组织有力，工作扎实，稳步推进，取得了明显的成效，受到了广大农民群众的欢迎，与此同时，我国明确扩大试点的目标和要求，加大中央和地方财政的支持力度，不断完善 合作医疗资金筹集和监管机制，合理制定和调整农民医疗费用补偿方案，以推动新型农村合作医疗登上新台阶。

从2009年开始，在政策支持力度加大、医院IT应用意识增强、移动智能终端普及加速、运营商解决推动等多方面因素的影响下，国内医疗信息化行业快速发展。2012年中国医疗信息化市场规模约199.1亿元，较2011年同比增长32.5%.

2000年以来，由于医疗美容行业存在的巨大商机引起了社会各界的关注，同时行业内开始扩张规模，经营的范围和规模不断扩大，仪器美容的优势也在不断提升，激光美容显现出了强劲的优势。医疗美容方面由过去的单一项目发展到了综合项目，手术的难度开始逐渐升级，丰胸、吸脂、除皱项目几乎在所有的民营机构营业项目中均都标出。此时，专业人才缺乏的现象凸显出来，使得民营美容机构的管理者开始求助于北京、上海、西安、沈阳、南京、重庆等地的几所大专院校的整形美容专业教授们。一时间出现整形美容专家教授满天飞的现象，自封的“专家”、“教授”也越来越多，尚不具备主治医师资格的住院医师也被戴上了“专家”、“教授”的头衔。另一方面在设施和治疗环境上也未达到医院标准要求，加之各级人员的素质低下，医生、护士的专业基础知识不够强。经专家教授术后的观察处理及护理均未跟上，使手术效果大打折扣，更有甚者出现了严重的医疗事故，此期内的美容整形手术后纠纷逐渐增多，有的医疗美容机构内几年下来积累的纠纷案例数以百计。

The Global Intravenous Solutions market has been experiencing steady growth for the past few years. Most of the growth in the global market in 2013 stems from the Americas and the EMEA region, and both of these regions together account for approximately 90 percent of the market share. The APAC region is expected to grow at a faster pace owing to the rapid adoption of intravenous solutions and the increasing awareness among the global population about benefits offered by intravenous solutions. The overall market is expected to grow at a CAGR of 7.88 percent during the forecast period.

The US is the most developed and active market across the globe in the area of clinical research. As of June '2013,69,659 clinical studies have been registered in the country. The state of California contributes the maximum to a number of clinical studies registered in the country with 18,808 clinical studies as of June,2013. A leader in medical innovation and researches, the US currently faces substantial challenges hampering the effective and efficient conduct of clinical research in the country. The clinical research scenario in the country is neither satisfying the current health care needs of the society nor is observing pace with the changes in the organization of health care system.

回顾我国新农合大病保障制度的发展过程，分析政策执行现状和运行效果，为完善政策提供参考。方法：利用政策分析方法，分析新农合大病医疗保障政策的形成背景、执行与效果，其中定量资料用描述性统计方法进行分析。结果：自2010年政策启动，新农合大病保障的病种及试点范围稳步扩大，2012年全国大病保障有99.6万名患者受益，受益率为12.45人次/10万参合人口，东部地区受益率高于中部和西部地区；全国20种大病实际补偿比达65.39%，儿童两病等4类大病的实际补偿比超过70%，中部地区补偿水平略高于东部和西部地区。结论：新农合重大疾病保障政策推进良好，基本实现政策目标，但区域间保障待遇存在差异，保障受益面有待进一步提高，可持续发展也面临挑战。建议：多种方式提高新农合大病保障水平，处理好新农合大病与一般疾病保障的关系，促进保障工作的可持续发展，加强对政策实施的监督与评价。

The mission of the U.S. Environmental Protection Agency's (EPA's) Office of Pesticide Programs (OPP) is to protect human health and the environment from potential risks associated with pesticide use. When used properly, pesticides can help control disease-causing organisms and foster a safe and abundant food supply. It is OPP's goal to ensure that pesticides marketed in the United States are sold, distributed, and used in a way that is protective of people's health, particularly that of vulnerable populations like children. This requires that the Office use the best available science when reaching regulatory decisions, find ways to communicate those decisions effectively, develop educational and training opportunities to help pesticide users make informed choices, and ensure proper implementation of pesticide statutes.